BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37462782)

  • 1. Progress in the Understanding of Estrogen Receptor Alpha Signaling in Triple-Negative Breast Cancer: Reactivation of Silenced ER-α and Signaling through ER-α36.
    Al-Kabariti AY; Abbas MA
    Mol Cancer Res; 2023 Nov; 21(11):1123-1138. PubMed ID: 37462782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
    Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
    J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in breast cancer.
    Zhao Y; Deng C; Lu W; Xiao J; Ma D; Guo M; Recker RR; Gatalica Z; Wang Z; Xiao GG
    Mol Med; 2011; 17(11-12):1233-41. PubMed ID: 21826373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
    Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
    Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer.
    Pan C; Hu Y; Li J; Wang Z; Huang J; Zhang S; Ding L
    PLoS One; 2014; 9(8):e104459. PubMed ID: 25127034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.
    Zhang XT; Kang LG; Ding L; Vranic S; Gatalica Z; Wang ZY
    Oncogene; 2011 Feb; 30(7):770-80. PubMed ID: 20935677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
    Zhang X; Deng H; Wang ZY
    J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.
    Wang ZY; Yin L
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.
    Tong JS; Zhang QH; Wang ZB; Li S; Yang CR; Fu XQ; Hou Y; Wang ZY; Sheng J; Sun QY
    PLoS One; 2010 Nov; 5(11):e15408. PubMed ID: 21079811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.
    Shi L; Dong B; Li Z; Lu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Wang Z; Xie Y
    J Clin Oncol; 2009 Jul; 27(21):3423-9. PubMed ID: 19487384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen-independent effects of ER-α36 in ER-negative breast cancer.
    Zhang J; Li G; Li Z; Yu X; Zheng Y; Jin K; Wang H; Gong Y; Sun X; Teng X; Cao J; Teng L
    Steroids; 2012 May; 77(6):666-73. PubMed ID: 22402113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the understanding of the structure and function of ER-α36,a novel variant of human estrogen receptor-alpha.
    Rao J; Jiang X; Wang Y; Chen B
    J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):231-7. PubMed ID: 21888973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative profiles of the mRNAs of ER-alpha and its novel variant ER-alpha36 in breast cancers and matched normal tissues.
    Zheng Y; Zhang J; Xu ZZ; Sheng JM; Zhang XC; Wang HH; Teng XD; Liu XJ; Cao J; Teng LS
    J Zhejiang Univ Sci B; 2010 Feb; 11(2):144-50. PubMed ID: 20104649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway.
    Zhu L; Zou J; Zhao Y; Jiang X; Wang Y; Wang X; Chen B
    J Exp Clin Cancer Res; 2018 Jun; 37(1):123. PubMed ID: 29940998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
    Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
    Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling.
    Wang Z; Zhang X; Shen P; Loggie BW; Chang Y; Deuel TF
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9063-8. PubMed ID: 16754886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas.
    Lee LM; Cao J; Deng H; Chen P; Gatalica Z; Wang ZY
    Anticancer Res; 2008; 28(1B):479-83. PubMed ID: 18383888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells.
    Deng H; Zhang XT; Wang ML; Zheng HY; Liu LJ; Wang ZY
    PLoS One; 2014; 9(2):e88034. PubMed ID: 24558373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.